Yader Sandoval1, Suzette J Bielinski2, Lori B Daniels3, Michael J Blaha4, Erin D Michos4, Andrew P DeFilippis5, Moyses Szklo6, Christopher deFilippi7, Nicholas B Larson8, Paul A Decker8, Allan S Jaffe9. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: https://twitter.com/yadersandoval. 2. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 3. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, California. 4. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 5. Division of Cardiovascular Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky. 6. Department of Epidemiology, The John Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. 7. Inova Heart and Vascular Institute, Falls Church, Virginia. 8. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 9. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: jaffe.allan@Mayo.edu.
Abstract
BACKGROUND: Low values of high-sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (CAC) scores of zero are associated with a low risk for atherosclerotic cardiovascular disease (ASCVD). OBJECTIVES: The purpose of this study was to evaluate baseline hs-cTnT and CAC in relation to ASCVD. METHODS: Baseline hs-cTnT (limit of detection [LoD] 3 ng/l) and CAC measurements were analyzed across participants age 45 to 84 years without clinical cardiovascular disease from the prospective MESA (Multi-Ethnic Study of Atherosclerosis) in relationship to incident ASCVD. RESULTS: Among 6,749 participants, 1,002 ASCVD events occurred during a median follow-up of 15 years. Participants with detectable CAC (20.1 vs. 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% confidence interval [CI]: 2.0 to 2.76; p < 0.001) and detectable hs-cTnT (15.4 vs. 5.2 per 1,000 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77; p < 0.001) had higher rates of ASCVD than those with undetectable results. Individuals with undetectable hs-cTnT (32%) had similar risk for ASCVD as did those with a CAC of zero (50%) (5.2 vs. 5.0 per 1,000 person-years). Together, hs-cTnT and CAC (discordance 38%) resulted in the following ASCVD event rates: hs-cTnT < LoD/CAC = 0: 2.8 per 1,000 person-years (reference), hs-cTnT ≥ LoD/CAC = 0: 6.8 per 1,000 person-years (HR: 1.59; 95% CI: 1.17 to 2.16; p = 0.003), hs-cTnT < LoD/CAC > 0: 11.1 per 1,000 person-years (HR: 2.74; 95% CI: 1.96 to 3.83; p < 0.00001), and hs-cTnT ≥ LoD/CAC > 0: 22.6 per 1,000 person-years (HR: 3.50; 95% CI: 2.60 to 4.70; p < 0.00001). CONCLUSIONS: An undetectable hs-cTnT identifies patients with a similar, low risk for ASCVD as those with a CAC score of zero. The increased risk among those with discordant results supports their conjoined use for risk prediction.
BACKGROUND: Low values of high-sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (CAC) scores of zero are associated with a low risk for atherosclerotic cardiovascular disease (ASCVD). OBJECTIVES: The purpose of this study was to evaluate baseline hs-cTnT and CAC in relation to ASCVD. METHODS: Baseline hs-cTnT (limit of detection [LoD] 3 ng/l) and CAC measurements were analyzed across participants age 45 to 84 years without clinical cardiovascular disease from the prospective MESA (Multi-Ethnic Study of Atherosclerosis) in relationship to incident ASCVD. RESULTS: Among 6,749 participants, 1,002 ASCVD events occurred during a median follow-up of 15 years. Participants with detectable CAC (20.1 vs. 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% confidence interval [CI]: 2.0 to 2.76; p < 0.001) and detectable hs-cTnT (15.4 vs. 5.2 per 1,000 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77; p < 0.001) had higher rates of ASCVD than those with undetectable results. Individuals with undetectable hs-cTnT (32%) had similar risk for ASCVD as did those with a CAC of zero (50%) (5.2 vs. 5.0 per 1,000 person-years). Together, hs-cTnT and CAC (discordance 38%) resulted in the following ASCVD event rates: hs-cTnT < LoD/CAC = 0: 2.8 per 1,000 person-years (reference), hs-cTnT ≥ LoD/CAC = 0: 6.8 per 1,000 person-years (HR: 1.59; 95% CI: 1.17 to 2.16; p = 0.003), hs-cTnT < LoD/CAC > 0: 11.1 per 1,000 person-years (HR: 2.74; 95% CI: 1.96 to 3.83; p < 0.00001), and hs-cTnT ≥ LoD/CAC > 0: 22.6 per 1,000 person-years (HR: 3.50; 95% CI: 2.60 to 4.70; p < 0.00001). CONCLUSIONS: An undetectable hs-cTnT identifies patients with a similar, low risk for ASCVD as those with a CAC score of zero. The increased risk among those with discordant results supports their conjoined use for risk prediction.
Authors: Gino Lee; Raphael Twerenbold; Yunus Tanglay; Tobias Reichlin; Ursina Honegger; Max Wagener; Cedric Jaeger; Maria Rubini Gimenez; Thomas Hochgruber; Christian Puelacher; Milos Radosavac; Philipp Kreutzinger; Fabio Stallone; Petra Hillinger; Lian Krivoshei; Thomas Herrmann; Romy Mayr; Michael Freese; Damian Wild; Katharina M Rentsch; John Todd; Stefan Osswald; Michael J Zellweger; Christian Mueller Journal: Am Heart J Date: 2015-12-02 Impact factor: 4.749
Authors: Omar Dzaye; Zeina A Dardari; Miguel Cainzos-Achirica; Ron Blankstein; Moyses Szklo; Matthew J Budoff; Joao A C Lima; Roger S Blumenthal; Khurram Nasir; Michael J Blaha Journal: J Am Coll Cardiol Date: 2020-04-07 Impact factor: 24.094
Authors: Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: Lieke J J Klinkenberg; Jan-Willem van Dijk; Frans E S Tan; Luc J C van Loon; Marja P van Dieijen-Visser; Steven J R Meex Journal: J Am Coll Cardiol Date: 2014-02-26 Impact factor: 24.094
Authors: Evangelos Giannitsis; Kerstin Kurz; Klaus Hallermayer; Jochen Jarausch; Allan S Jaffe; Hugo A Katus Journal: Clin Chem Date: 2009-12-03 Impact factor: 8.327
Authors: Ian Ford; Anoop S V Shah; Ruiqi Zhang; David A McAllister; Fiona E Strachan; Muriel Caslake; David E Newby; Chris J Packard; Nicholas L Mills Journal: J Am Coll Cardiol Date: 2016-12-27 Impact factor: 24.094
Authors: Anoop S V Shah; Atul Anand; Yader Sandoval; Kuan Ken Lee; Stephen W Smith; Philip D Adamson; Andrew R Chapman; Timothy Langdon; Dennis Sandeman; Amar Vaswani; Fiona E Strachan; Amy Ferry; Alexandra G Stirzaker; Alan Reid; Alasdair J Gray; Paul O Collinson; David A McAllister; Fred S Apple; David E Newby; Nicholas L Mills Journal: Lancet Date: 2015-10-08 Impact factor: 202.731
Authors: Ty Sweeney; Renato Quispe; Thomas Das; Stephen P Juraschek; Seth S Martin; Erin D Michos Journal: Expert Rev Precis Med Drug Dev Date: 2021-05-26
Authors: Mariola Olkowicz; Izabela Czyzynska-Cichon; Natalia Szupryczynska; Renata B Kostogrys; Zdzislaw Kochan; Janusz Debski; Michal Dadlez; Stefan Chlopicki; Ryszard T Smolenski Journal: J Transl Med Date: 2021-01-06 Impact factor: 5.531
Authors: Dorien M Kimenai; Anoop S V Shah; David A McAllister; Kuan Ken Lee; Athanasios Tsanas; Steven J R Meex; David J Porteous; Caroline Hayward; Archie Campbell; Naveed Sattar; Nicholas L Mills; Paul Welsh Journal: Clin Chem Date: 2021-10-01 Impact factor: 12.167